Cargando…

Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational Psoriasis Study of Health Outcomes (PSoHO)

INTRODUCTION: Psoriasis localized at the scalp, face, nails, genitalia, palms, and soles can exacerbate the disease burden. Real-world studies comparing the effectiveness of treatments for these special areas are limited. METHODS: Psoriasis Study of Health Outcomes (PSoHO) is an international, prosp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Piaserico, Stefano, Riedl, Elisabeth, Pavlovsky, Lev, Vender, Ronald B., Mert, Can, Tangsirisap, Nithi, Haustrup, Natalie, Gallo, Gaia, Schuster, Christopher, Brunner, Patrick M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339811/ https://www.ncbi.nlm.nih.gov/pubmed/37457564 http://dx.doi.org/10.3389/fmed.2023.1185523

Ejemplares similares

Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting
por: Lynde, Charles, et al.
Publicado: (2022)

Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
por: Travaglini, Massimo, et al.
Publicado: (2023)

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
por: EGEBERG, Alexander, et al.
Publicado: (2022)

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest
por: Reich, K., et al.
Publicado: (2015)

Implementation of the PsoWell™ Model for the Management of People with Complex Psoriasis
por: HEWITT, Rachael M., et al.
Publicado: (2021)

Tapinarof for the treatment of psoriasis
por: Nogueira, Sofia, et al.
Publicado: (2022)

The Value of Indirect Comparisons of Systemic Biologics for Psoriasis: Interpretation of Efficacy Findings
por: Augustin, Matthias, et al.
Publicado: (2022)

Nail psoriasis as a severity indicator: results from the PsoReal study
por: Radtke, Marc A, et al.
Publicado: (2010)

Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Psoriasis and Cardiometabolic Diseases: Shared Genetic and Molecular Pathways
por: Piaserico, Stefano, et al.
Publicado: (2022)

Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso
por: Wellmann, Phoebe, et al.
Publicado: (2022)

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate‐to‐severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI‐PSO study
por: Richard, M.‐A., et al.
Publicado: (2020)

Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA)
por: Graier, T., et al.
Publicado: (2022)

A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians
por: Drakos, Anastasia, et al.
Publicado: (2022)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
por: Wasel, Norman, et al.
Publicado: (2020)

Psoriasis, biologic therapy, and the pandemic of the 21st century
por: Nogueira, Miguel, et al.
Publicado: (2020)

Viewpoint about biologic agents for psoriasis: are they immunosuppressants or immunomodulators?
por: Metko, Dea, et al.
Publicado: (2023)

Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab
por: Brunner, P.M., et al.
Publicado: (2021)

PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis
por: Stein Gold, Linda, et al.
Publicado: (2020)

Psoriasis pathogenesis – Pso p27 constitutes a compact structure forming large aggregates
por: Lysvand, Hilde, et al.
Publicado: (2015)

CoronaBest und PsoBest Bioscience: Neue Ausbaustufen beim Deutschen Psoriasis-Register
por: Gehoff, Mario
Publicado: (2020)

Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
por: Gargiulo, Luigi, et al.
Publicado: (2023)

Systemic Role for Vitamin D in the Treatment of Psoriasis and Metabolic Syndrome
por: Fu, Lisa Wenyang, et al.
Publicado: (2011)

Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?
por: Orlando, Gloria, et al.
Publicado: (2022)

Plaque psoriasis and morphea in a patient on ustekinumab: A case report
por: Cirone, Katrina, et al.
Publicado: (2023)

Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate‐to‐severe psoriasis: a post hoc analysis from IXORA‐PEDS
por: Seyger, M.M.B., et al.
Publicado: (2021)

Comments on ‘French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults’
por: Schuster, C., et al.
Publicado: (2019)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Kirkham, Bruce W., et al.
Publicado: (2023)

Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 1)
por: Lambert, J.L.W., et al.
Publicado: (2020)

Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire
por: Dauden, Esteban, et al.
Publicado: (2012)

Exploring the Association Between History of Psoriasis (PSO) and Disease Activity in Patients with Psoriatic Arthritis (PsA)
por: Li, Shan-Shan, et al.
Publicado: (2022)

Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool
por: Leonardi, Craig, et al.
Publicado: (2021)

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study
por: SHERMAN, Shany, et al.
Publicado: (2020)

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council
por: Cohen, Arnon D., et al.
Publicado: (2020)

Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA‐PSO: Belgian Evidence‐based Treatment Advice in Psoriasis; part 2)
por: Lambert, J.L.W., et al.
Publicado: (2020)

Development and psychometric evaluation of a new patient -reported outcome measure for psoriasis self-management efficacy: the self-management efficacy questionnaire among patients with psoriasis (SMEQ-PSO)
por: Sun, Yuanhui, et al.
Publicado: (2023)

Psoriasis in special localizations
por: Dopytalska, Klaudia, et al.
Publicado: (2018)

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study
por: GNESOTTO, Laura, et al.
Publicado: (2023)

Psoriasis Prevalence and Severity by Expert Elicitation
por: Papp, Kim A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_90i4spuiqvv238l3vg1lojduur